Clinical Trials

Are you an adult with a diagnosed sleep phase disorder? This study aims to assess the sleep patterns and quality of sleep in people who have sleep phase disorders to determine how the disorders affect their circadian rhythms. To participate in this study, you must be at least 18 years old and have a sleep phase disorder, such as advanced sleep-wake phase syndrome or delayed sleep-wake phase syndrome. This study is located in Chicago, Illinois.

Do you have overweight? Circadian rhythm disorders can cause overweight and obesity. This study is examining how not getting enough sleep causes these complications. To participate in this study, you must be between the ages of 20 and 40 and have overweight but not obesity. This study is located in New York, New York.

Are you a healthy adult who regularly sleeps for 6.5 or fewer hours? This study is examining whether getting enough sleep can lower your risk of high blood pressure. To participate in this study, you must be between 18 and 65 years old, regularly sleep for 6.5 or fewer hours, and be able to adjust your sleep schedule for the study. This study is located in Rochester, Minnesota.

Are you an adult who does not have high blood pressure? Circadian rhythms control daytime and nighttime changes in blood pressure. This study is examining the links between stress, loss of sodium through urine, and circadian rhythms in controlling blood pressure. To participate in this study, you must be at least 21 years old and not have high blood pressure. This study is located in New York, New York.

This study aims to see if a blood test can predict rejection and take the place of biopsies. The test shows how much donor DNA is in a recipient s blood. Adults 18 years and older who are on the lung or heart transplant waitlist are eligible.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

This is an observational - data and specimen collection study. There have been increasing reports of vaping-induced lung injury, including severe lung injury and rare cases of death. The mechanism by which vaping contributes to lung injury in susceptible persons is unknown, as is impact on chronic lung disease. The investigators aim to identify individuals with chronic electronic nicotine delivery device (ENDD) exposure and matched controls within our ongoing cohort of HIV+ and HIV-uninfected individuals, collect PFT data, bank respiratory and stool samples and collect clinical data for studies of clinical risk, inflammation, biomarkers, and the microbiome in the identification and modification of risk of progression to lung injury or chronic pulmonary disease.

This study will pilot test a just-in-time (JIT) adaptive intervention to reduce severe respiratory illness, for children with severe cerebral palsy (CP). The intervention program, called RE-PACT, delivers timely, customized action planning and health coaching when mobile text messaging with families predicts hospitalization risk is elevated. A total of n=90 caregivers of children with severe CP will be enrolled from the University of Wisconsin-Madison (UW) and the University of California, Los Angeles (UCLA) and can expect to be on study for up to 6 months.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA).